Results 41 to 50 of about 80,018 (239)

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? [PDF]

PLoS ONE, 2008
Scleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated with scleroderma is one of the major contributors to the clinical manifestations of the disease.We used immunohistochemical and mRNA in situ ...
Jo N Fleming, Richard A Nash, D O McLeod, David F Fiorentino, Howard M Shulman, M Kari Connolly, Jerry A Molitor, Gretchen Henstorf, Robert Lafyatis, David K Pritchard, Lawrence D Adams, Daniel E Furst, Stephen M Schwartz   +12 more
doaj   +1 more source

Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with diffuse scleroderma

Indian Journal of Rheumatology, 2021
Scleroderma is a multiorgan connective tissue disease characterized by autoantibody production and fibroproliferative stenosis of the microvasculature. The development of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in patients with ...
B N Shiva Prasad, H A Karthik Urala
doaj   +1 more source

A Case Report of Systemic Sclerosis Complicated by Biventricular Heart Failure, Pulmonary Hypertension and Review of Literature [PDF]

, 2017
Background: Systemic sclerosis (SSc) is an autoimmune connective tissue disorder whose aetiology is not fully understood. Skin fibrosis and visceral organs involvement are the hallmarks, and the heart could be disproportionately or subtly involved ...
Akinboro AO, Akinlade M, Akintunde AA, Audu MB   +3 more
core   +1 more source

Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database

Drugs - Real World Outcomes, 2023
Background Immune checkpoint inhibitors (ICIs) can be commonly associated with the occurrence of immune-related adverse drug reactions (irADRs), which can involve any tissue and organ.
Maria Maddalena Nicoletti, Erminia Crisci, Vincenzo Cosenza, Consiglia Riccardi, Maria Rosaria Campitiello, Donatella Ruggiero, Pasquale Maria Berrino, Giovanni Docimo, Cristina Scavone   +8 more
doaj   +1 more source

Longitudinal Assessment of the Juvenile Systemic Sclerosis Severity Score: Application in the National Registry for Childhood Onset Scleroderma [PDF]

ACR Open Rheumatol
Objective Juvenile‐onset systemic sclerosis (jSSc) is a rare, heterogeneous pediatric autoimmune disease. Existing severity tools are often adapted from adult systemic sclerosis and lack pediatric‐specific validation. The Juvenile Systemic Sclerosis Severity Score (J4S) was developed to address this gap by capturing multiorgan disease burden.
Branton S, Torok K.
europepmc   +2 more sources

Innate Immune Modulation Induced by EBV Lytic Infection Promotes Endothelial Cell Inflammation and Vascular Injury in Scleroderma

Frontiers in Immunology, 2021
Microvascular injury is considered an initial event in the pathogenesis of scleroderma and endothelial cells are suspected of being the target of the autoimmune process seen in the disease. EBV has long been proposed as a trigger for autoimmune diseases,
Antonella Farina, Edoardo Rosato, Michael York, Benjamin E. Gewurz, Benjamin E. Gewurz, Benjamin E. Gewurz, Maria Trojanowska, Giuseppina Alessandra Farina   +7 more
doaj   +1 more source

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]

, 2016
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +1 more
core   +2 more sources

Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis–Associated Interstitial Lung Disease

Arthritis Care &Research, EarlyView.
Objective A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M. Padilla, Robert Lafyatis, Kevin F. Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, Jonathan Minden, Robyn Domsic, Yingze Zhang, Daniel J. Kass   +13 more
wiley   +1 more source

Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents

Arthritis Research & Therapy
Background Autologous haematopoietic stem cell transplantation (AHSCT) is more effective than conventional immunosuppressive therapies (CIT) in improving the outcome of patients with rapidly progressive diffuse cutaneous systemic sclerosis (dcSSc).
Nicoletta Del Papa, Silvia Cavalli, Andrea Rindone, Francesco Onida, Giorgia Saporiti, Antonina Minniti, Maria Rosa Pellico, Claudia Iannone, Giorgia Trignani, Nicoletta D’Angelo, Manuel Sette, Raffaella Greco, Claudio Vitali, Roberto Caporali   +13 more
doaj   +1 more source

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?

Arthritis Research & Therapy, 2017
Systemic sclerosis is considered a disease dominated by a “loss of angiogenesis”, although in its early phases evidence indicates a disturbed angiogenic response only.
Marco Matucci-Cerinic, Mirko Manetti, Cosimo Bruni, Ines Chora, Silvia Bellando-Randone, Gemma Lepri, Amato De Paulis, Serena Guiducci   +7 more
doaj   +1 more source